Rinvoq ER 15 MG tablet UU 30S
Ended Awarded Last action
- Contract number
- SPE2DR26FM9F7
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $13,062
Award facts
- Contract value 100% obligated
- $13,061.94 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $13,061.94 firm fixed-price delivery order to AmerisourceBergen Drug Corp on January 8, 2026, for RINVOQ ER 15 mg tablets (30-count units), with final delivery due January 9, 2026. This non-set-aside award was competitively procured and is being performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The order represents a task order execution under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (valued at up to $999,999,999.00 through December 2026), which serves as a comprehensive global pharmaceutical support vehicle for military healthcare systems worldwide.
AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc., operates as a major pharmaceutical distributor and critical vendor for federal medical procurement. The company has demonstrated extensive capability in fulfilling diverse pharmaceutical needs for military and veteran healthcare systems, supplying brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains. This delivery order for RINVOQ (upadacitinib), a Janus kinase inhibitor used for rheumatoid arthritis and other inflammatory conditions, exemplifies the routine pharmaceutical supply operations AmerisourceBergen executes through its strategic partnership with the Defense Logistics Agency's medical supply chain.
Quick answers
Who was awarded contract SPE2DR26FM9F7?
SPE2DR26FM9F7 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 8, 2026.
How much is contract SPE2DR26FM9F7 worth?
The government has obligated $13,062 on SPE2DR26FM9F7.
Is contract SPE2DR26FM9F7 an order under another contract?
Yes. SPE2DR26FM9F7 is a delivery order under SPE2DR25D2211, an indefinite delivery contract.
Was contract SPE2DR26FM9F7 competed?
The extent of competition for SPE2DR26FM9F7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award